ImmunoCellular Therapeutics, Ltd., based in Los Angeles, is developing immune-based therapies for the treatment of cancer. ImmunoCellular is focused on advancing its Stem-to-T-Cell research program, which engineers hematopoietic stem cells to generate cytotoxic T cells. Additional assets, for which the Company is seeking partners, include clinical-stage programs - ICT-107, ICT-121 and ICT-140 - which are patient-specific, dendritic cell-based immunotherapies targeting solid tumors.
Location: United States, California, Westlake Village
Phone: +1 818-264-2300
Investors 1
| Date | Name | Website |
| - | Asset Mana... | assetman.c... |
Mentions in press and media 3
| Date | Title | Description |
| 28.06.2021 | ImmunoCellular Therapeutics Announces Application for Continued Public Quoting on the Over-the-Counter (OTC) Market | |
| 02.01.2013 | A two-pronged approach to immunotherapy for brain, kidney cancers gets $2 million from investors | TVAX’s approach to immunotherapy is two-fold: vaccinate the patient with a combination of his own cancer cells and a powerful adjuvant, then use the partially activated T cells generated by that vaccine to manufacture high numbers of activa... |
| - | A two-pronged approach to immunotherapy for brain, kidney cancers gets $2 million from investors | UPDATED 1/7/13 After withdrawing an initial public offering early last summer, a company employing a two-pronged approach to immunotherapy is raising private capital as it looks toward phase 3 trials of brain and kidney cancer drugs. A Dece... |